Bristol-Myers Squibb confirmed that it halted pivotal studies of the experimental IDO inhibitor BMS-986205 in three tumor types in the wake of a recent late-stage trial failure for Incyte’s investigational IDO1 inhibitor epacadostat. Bristol-Myers Squibb said “we believe it is important to follow the science to make decisions that will result in clinically meaningful outcomes for patients.”…